The Asia Pacific deep brain stimulation device market size was estimated at USD 310 million in 2025 and is projected to be worth around USD 1,071.09 million by 2035, is projected to expand at a CAGR of 13.20% from 2026 to 2035. The market growth is driven by improving healthcare infrastructure and expanding access to specialized neurology centres.

Asia Pacific Deep Brain Stimulation Devices Market Statical Scope

The Asia Pacific is emerging as the fastest growing deep brain stimulation device market due to improving healthcare infrastructure and rising neurological disease prevalence. Countries including China, Japan, India, and South Korea are witnessing increasing awareness of advanced neurostimulation therapies among healthcare professionals and patients. Expanding healthcare expenditure, improving access to specialised neurology centres, and a rapidly increasing ageing population are driving the market.

The government in the region is supporting investments in neuroscience research and advanced medical technologies, and creating favourable conditions for market expansion. International manufacturers are expanding their regional presence through partnerships and distribution networks. The growing demand for effective long term treatment alternatives for Parkinson's disease and epilepsy is accelerating DBS adoption across the Asia Pacific.

Asia Pacific Deep Brain Stimulation Devices Market Share, By Product Outlook, 2025, (%)

• Single Channel DBS - Single Channel DBS leads the segment, with a share of 38%, driven by earlier adoption, lower procedural cost, and established clinical use in neuromodulation therapy.
• Dual Channel DBS - Dual Channel DBS hold a significant portion, with a share of 62%, supported by improved clinical outcomes, higher precision targeting, and growing preference for advanced stimulation systems.

Asia Pacific Deep Brain Stimulation Devices Market Share, By Application outlook, 2025, (%)

• Pain Management - Pain Management leads the segment, with a share of 10%. Rising neurological disease burden and limited pain control options drive increasing interest in DBS for refractory pain conditions.
• Epilepsy - Epilepsy holds a significant portion, with a share of 15%. Growing epilepsy prevalence and improving diagnosis rates support deep brain stimulation adoption in treatment resistant cases.
• Essential Tremor - Essential Tremor accounts for 45%, driven by an ageing population and rising awareness regarding advanced movement disorder therapies.

Asia Pacific Deep Brain Stimulation Devices Market Share, By End Use Outlook, 2025, (%)

• Hospitals - Hospitals lead the segment, with a share of 66%, driven by advanced neurosurgical infrastructure, skilled professionals, availability of emergency care units and high procedure volumes.
• Neurology Clinics - Neurology Clinics hold a significant portion, with a share of 16%. Rising access to trained neurologists and expanding urban healthcare networks support treatment adoption.
• Ambulatory Surgical Centers - Ambulatory Surgical Centres account for 12%, driven by healthcare modernization and growing adoption of minimally invasive surgical procedures. Patients are increasingly choosing cost-effective treatment settings that offer shorter hospital stays and faster recovery.
• Research Centers - Research Centers hold 6%, supported by increasing neuroscience investments and international collaborations, ongoing clinical trials and neuromodulation research activities.

Recent Developments in the Market

• In April 2026, Medtronic plc, a global leader in healthcare technology, introduced its Adaptive Deep Brain Stimulation system in India for Parkinson's disease patients. This launch helps in broader regional access for advanced neuromodulation therapies and extends Medtronic's neuromodulation footprints across the country.
• In April 2026, Healing Hospital Chandigarh announced the launch of Adaptive Deep Brain Stimulation (aDBS) to treat Parkinson's disease. Adaptive DBS is an advanced procedures which monitors real-time brain signals and automatically adjusts stimulation levels to offer a more precise and personalized approach to treating Parkinson's disease.

Competitive Landscape

• Key Participants in the Asia Pacific deep brain stimulation device market include Boston Scientific Corporation, Fisher Wallace, SceneRay Corporation, Limited, Beijing PINS Medical Co., Ltd, ALEVA NEUROTHERAPEUTICS SA, MEDTRONIC, Abbott, Deep Brain Innovations, LLC, St. Jude Children's Research Hospital, Stanford Health Care, NeuroPace Inc, Renishaw plc, and Functional Neuromodulation Ltd. The region holds the world's largest patient volume, with increasing Parkinson's disease cases in China and India.
• Medtronic plc is a global leader in the medical device market. It focuses on building partnerships with elite university research hospitals in Japan and the Asia Pacific countries to expand the company's growth.
• PINS Medical is a domestic Chinese company that offers key products such as PINS Rechargeable DBS System and PINS Single / Dual Channel Stimulators.
• SceneRay Corporation is a Chinese company providing popular products such as Neurestors DBS System and Dual Target combined Stimulation Systems.

Segment Covered in the Report

By Product

• Single Channel
• Dual Channel

By Application

• Pain Management
• Epilepsy
• Essential Tremor
• Obsessive-compulsive Disorders (OCD)
• Depression
• Dystonia
• Parkinson's Disease
• Others

By End-use

• Hospitals
• Neurology Clinics
• Ambulatory Surgical Centers
• Research Centers